Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.

Abstract:

Background:Glioblastoma cell-initiated vascularization is an alternative angiogenesis called vasculogenic mimicry. However, current knowledge on the mechanism of de novo vessel formation from glioblastoma stem cells (GSCs) is limited. Methods:Sixty-four glioblastoma samples from patients and 10 fluorescent glioma xenograft samples were examined by immunofluorescence staining for endothelial marker (CD34 and CD31) and glial cell marker (glial fibrillary acidic protein [GFAP]) expression. GSCs were then isolated from human glioblastoma tissue and CD133+/Sox2+ red fluorescent protein-containing (RFP)-GSC-1 cells were established. The ability of these cells to form vascular structures was examined by live-cell imaging of 3D cultures. Results:CD34-GFAP or CD31-GFAP coexpressing glioblastoma-derived endothelial cells (GDEC) were found in 30 of 64 (46.9%) of clinical glioblastoma samples. In those 30 samples, GDEC were found to form vessel structures in 21 (70%) samples. Among 21 samples with GDEC vessels, the CD34+ GDEC vessels and CD31+ GDEC vessels accounted for about 14.16% and 18.08% of total vessels, respectively. In the xenograft samples, CD34+ GDEC were found in 7 out of 10 mice, and 4 out of 7 mice had CD34+ GDEC vessels. CD31+ GDEC were also found in 7 mice, and 4 mice had CD31+ GDEC vessels (10 mice in total). Through live-cell imaging, we observed gradual CD34 expression when cultured with vascular endothelial growth factor in some glioma cells, and a dynamic increase in endothelial marker expression in RFP-GSC-1 in vitro was recorded. Cells expressed CD34 (9.46%) after 6 hours in culture. Conclusions:The results demonstrated that GSCs may differentiate into endothelial cells and promote angiogenesis in glioblastomas.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Mei X,Chen YS,Chen FR,Xi SY,Chen ZP

doi

10.1093/neuonc/nox016

subject

Has Abstract

pub_date

2017-08-01 00:00:00

pages

1109-1118

issue

8

eissn

1522-8517

issn

1523-5866

pii

3063804

journal_volume

19

pub_type

杂志文章
  • A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.

    abstract::Glial tumors with oligodendroglial components are considered chemo-responsive. Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m(2) on days 1-5 e...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1093/neuonc/nop065

    authors: Gan HK,Rosenthal MA,Dowling A,Kalnins R,Algar E,Wong N,Benson A,Woods AM,Cher L

    更新日期:2010-05-01 00:00:00

  • Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma.

    abstract::In the present study we described the role of alpha9beta1 integrin in glioblastoma progression following its interaction with nerve growth factor (NGF). The level of expression of alpha9beta1 on astrocytomas is correlated with increased grade of this brain tumor and is highest on glioblastoma, whereas normal astrocyte...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-047

    authors: Brown MC,Staniszewska I,Lazarovici P,Tuszynski GP,Del Valle L,Marcinkiewicz C

    更新日期:2008-12-01 00:00:00

  • Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases.

    abstract:BACKGROUND:The objective was to evaluate the risk and predictors of developing leptomeningeal disease (LMD) in patients with brain metastases treated with 5-fraction hypofractionated stereotactic radiotherapy (HSRT). METHODS:Patients treated with HSRT for intact brain metastases and/or surgical cavities were reviewed ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz144

    authors: Nguyen TK,Sahgal A,Detsky J,Atenafu EG,Myrehaug S,Tseng CL,Husain Z,Heyn C,Maralani P,Ruschin M,Perry J,Soliman H

    更新日期:2020-01-11 00:00:00

  • Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.

    abstract:BACKGROUND:Glioblastoma multiforme, a World Health Organization grade IV glioma, has a poor prognosis in humans despite current treatment options. Here, we present magnetic resonance imaging (MRI) data regarding the regression of aggressive rat F98 gliomas and human U87 glioma xenografts after treatment with the nitron...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos337

    authors: Towner RA,Gillespie DL,Schwager A,Saunders DG,Smith N,Njoku CE,Krysiak RS 3rd,Larabee C,Iqbal H,Floyd RA,Bourne DW,Abdullah O,Hsu EW,Jensen RL

    更新日期:2013-03-01 00:00:00

  • Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications.

    abstract::Gliomas are a heterogeneous group of brain tumors with distinct biological and clinical properties. Despite advances in surgical techniques and clinical regimens, treatment of high-grade glioma remains challenging and carries dismal rates of therapeutic success and overall survival. Challenges include the molecular co...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox183

    authors: Malta TM,de Souza CF,Sabedot TS,Silva TC,Mosella MS,Kalkanis SN,Snyder J,Castro AVB,Noushmehr H

    更新日期:2018-04-09 00:00:00

  • Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.

    abstract::The objective of this study was to ascertain the duration of tumor control and the toxicities of dose-intense myeloablative chemotherapy for patients with recurrent oligodendrogliomas. Patients with previously irradiated oligodendrogliomas, either pure or mixed, that were contrast enhancing, measurable, and behaving a...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/2.2.114

    authors: Cairncross G,Swinnen L,Bayer R,Rosenfeld S,Salzman D,Paleologos N,Kaminer L,Forsyth P,Stewart D,Peterson K,Hu W,Macdonald D,Ramsay D,Smith A,Oligodendroglioma Study Group.

    更新日期:2000-04-01 00:00:00

  • Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

    abstract::Peripheral neuropathies induced by chemotherapy (CIPN) are an increasingly frequent problem. Contrary to hematologic adverse effects, which can be treated with hematopoetic growth factors, neither prophylaxis nor specific treatment is available, and only symptomatic treatment can be offered. Neurotoxic drugs are becom...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nos203

    authors: Grisold W,Cavaletti G,Windebank AJ

    更新日期:2012-09-01 00:00:00

  • Racial differences in primary central nervous system lymphoma incidence and survival rates.

    abstract::To determine racial and ethnic differences in incidence and survival in patients with primary central nervous system lymphoma (PCNSL), NCI Surveillance, Epidemiology, and End Results (SEER) program data from 1992 to 2002 were queried. Data were substratified by age (20-49 years vs. 50 or above) and race (White, Black,...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-103

    authors: Pulido JS,Vierkant RA,Olson JE,Abrey L,Schiff D,O'Neill BP

    更新日期:2009-06-01 00:00:00

  • Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.

    abstract::Glioblastoma multiforme (GBM) continues to be a difficult therapeutic challenge. Our study was conducted to determine whether improved survival and tumor control could be achieved with modern delivery of fast neutron radiation using three-dimensional treatment planning. Ten patients were enrolled. Eligibility criteria...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1215/15228517-2007-044

    authors: Stelzer KJ,Douglas JG,Mankoff DA,Silbergeld DL,Krohn KA,Laramore GE,Spence AM

    更新日期:2008-02-01 00:00:00

  • A low percentage of metastases in deep brain and temporal lobe structures.

    abstract:BACKGROUND:Whole-brain radiotherapy (WBRT) in patients with brain metastases (BM) is associated with neurocognitive decline. Given its crucial role in learning and memory, efforts to mitigate this toxicity have mostly focused on sparing radiation to the hippocampus. We hypothesized that BM are not evenly distributed ac...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz023

    authors: Yanagihara TK,McFaline-Figueroa JR,Giacalone NJ,Lee AW,Soni V,Hwang ME,Hsieh KT,Saraf A,Wu CC,Yang D,Wen PY,Ashamalla H,Aizer AA,Wang TJC,Huang RY

    更新日期:2019-05-06 00:00:00

  • Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).

    abstract:BACKGROUND:Young age is a favorable prognostic factor for patients with glioblastoma multiforme (GBM). We reviewed the outcomes and molecular tumor characteristics of adolescent and young adult patients with GBM treated in 2 Austrian centers. PATIENTS AND METHODS:Data on patients with histologically proven primary GBM...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos283

    authors: Leibetseder A,Ackerl M,Flechl B,Wöhrer A,Widhalm G,Dieckmann K,Kreinecker SS,Pichler J,Hainfellner J,Preusser M,Marosi C

    更新日期:2013-01-01 00:00:00

  • Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

    abstract:BACKGROUND:RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall survival (OS). METHODS:O...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1093/neuonc/not049

    authors: Boxerman JL,Zhang Z,Safriel Y,Larvie M,Snyder BS,Jain R,Chi TL,Sorensen AG,Gilbert MR,Barboriak DP

    更新日期:2013-07-01 00:00:00

  • Adult pilocytic astrocytomas: clinical features and molecular analysis.

    abstract:BACKGROUND:Adult pilocytic astrocytomas (PAs) are rare and have an aggressive clinical course compared with pediatric patients. Constitutive Ras/RAF/MAPK signaling appears to be an important oncogenic event in sporadic PA. We evaluated clinical data and molecular profiles of adult PAs at our institution. METHODS:We id...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not246

    authors: Theeler BJ,Ellezam B,Sadighi ZS,Mehta V,Tran MD,Adesina AM,Bruner JM,Puduvalli VK

    更新日期:2014-06-01 00:00:00

  • Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.

    abstract:BACKGROUND:The Cancer Genome Atlas (TCGA) project is a large-scale effort with the goal of identifying novel molecular aberrations in glioblastoma (GBM). METHODS:Here, we describe an in-depth analysis of gene expression data and copy number aberration (CNA) data to classify GBMs into prognostic groups to determine cor...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not024

    authors: Kim YW,Koul D,Kim SH,Lucio-Eterovic AK,Freire PR,Yao J,Wang J,Almeida JS,Aldape K,Yung WK

    更新日期:2013-07-01 00:00:00

  • Molecular and translational advances in meningiomas.

    abstract::Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treat...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/noy178

    authors: Suppiah S,Nassiri F,Bi WL,Dunn IF,Hanemann CO,Horbinski CM,Hashizume R,James CD,Mawrin C,Noushmehr H,Perry A,Sahm F,Sloan A,Von Deimling A,Wen PY,Aldape K,Zadeh G,International Consortium on Meningiomas.

    更新日期:2019-01-14 00:00:00

  • A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.

    abstract::Difficulties of drug delivery across the blood-brain barrier (BBB) and failure to eliminate cancer stem cells (CSCs) are believed to be the major causes of tumor recurrences in children with medulloblastoma (MB). Seneca Valley virus-001 (SVV-001) is a naturally occurring oncolytic picornavirus that can be systemically...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq148

    authors: Yu L,Baxter PA,Zhao X,Liu Z,Wadhwa L,Zhang Y,Su JM,Tan X,Yang J,Adesina A,Perlaky L,Hurwitz M,Idamakanti N,Police SR,Hallenbeck PL,Blaney SM,Chintagumpala M,Hurwitz RL,Li XN

    更新日期:2011-01-01 00:00:00

  • Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).

    abstract::On October 15, 2014, a workshop was held on the use of clinical outcome assessments in clinical trials for high-grade glioma of the brain. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, the Musella ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nov270

    authors: Helfer JL,Wen PY,Blakeley J,Gilbert MR,Armstrong TS

    更新日期:2016-03-01 00:00:00

  • Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.

    abstract:BACKGROUND:This study aimed to evaluate the prognostic significance of co-polsomy of chromosome 1q and 19p in 1p/19q codeleted oligodendroglial tumors (ODGs). METHODS:In a series of 148 ODGs with 1p/19q deletion, co-polysomy of 1q and 19p was detected by fluorescence in situ hybridization (FISH). Log-rank analysis and...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not092

    authors: Ren X,Jiang H,Cui X,Cui Y,Ma J,Jiang Z,Sui D,Lin S

    更新日期:2013-09-01 00:00:00

  • A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.

    abstract:BACKGROUND:Fatigue is common among glioma patients undergoing radiotherapy (RT) and impacts quality of life (QOL). We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT. METHODS:Eligibility criteria included age ≥18 years, Karnofsky performance status ≥...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1093/neuonc/now007

    authors: Lee EQ,Muzikansky A,Drappatz J,Kesari S,Wong ET,Fadul CE,Reardon DA,Norden AD,Nayak L,Rinne ML,Alexander BM,Arvold ND,Doherty L,Stefanik J,LaFrankie D,Ruland SF,Pulverenti J,Smith KH,Gaffey SC,Hammond S,Wen PY

    更新日期:2016-06-01 00:00:00

  • Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults.

    abstract::Radiotherapy is ubiquitous in the treatment of patients with both primary brain tumors as well as disease which is metastatic to the brain. This therapy is not without cost, however, as cognitive decline is frequently associated with cranial radiation, particularly with whole brain radiotherapy (WBRT). The precise mec...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox195

    authors: Wilke C,Grosshans D,Duman J,Brown P,Li J

    更新日期:2018-04-09 00:00:00

  • Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

    abstract::The objective of this study was to evaluate whether longitudinal levels of serum YKL-40 correlate with disease status or survival in adults with gliomas. Patients with histologically confirmed gliomas were eligible for this longitudinal study. Serum samples were collected prospectively and concurrently with MRI scans ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor117

    authors: Iwamoto FM,Hottinger AF,Karimi S,Riedel E,Dantis J,Jahdi M,Panageas KS,Lassman AB,Abrey LE,Fleisher M,DeAngelis LM,Holland EC,Hormigo A

    更新日期:2011-11-01 00:00:00

  • Brain metastases in melanoma: roles of neurotrophins.

    abstract::Brain metastasis, which occurs in 20% to 40% of all cancer patients, is an important cause of neoplastic morbidity and mortality. Successful invasion into the brain by tumor cells must include attachment to microvessel endothelial cells, penetration through the blood-brain barrier, and, of relevance, a response to bra...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1215/s115285170300067x

    authors: Denkins Y,Reiland J,Roy M,Sinnappah-Kang ND,Galjour J,Murry BP,Blust J,Aucoin R,Marchetti D

    更新日期:2004-04-01 00:00:00

  • Assessment and treatment relevance in elderly glioblastoma patients.

    abstract::Glioblastoma (GBM) is the most common malignant primary brain tumor. Its incidence continues to increase in the elderly because the older segment of the population is growing faster than any other age group. Most clinical studies exclude elderly patients, and "standards of care" do not exist for GBM patients aged >70 ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou063

    authors: Bauchet L,Zouaoui S,Darlix A,Menjot de Champfleur N,Ferreira E,Fabbro M,Kerr C,Taillandier L

    更新日期:2014-11-01 00:00:00

  • Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

    abstract::Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findings in glioblastomas. EGFR is at the top of a downstream signaling cascade that regulates important characteristics of glioblastoma cells, including cellular proliferation, migration, and survival. Targeting EGFR has th...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou222

    authors: Roth P,Weller M

    更新日期:2014-10-01 00:00:00

  • Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.

    abstract::Development of model systems that recapitulate the molecular heterogeneity observed among glioblastoma multiforme (GBM) tumors will expedite the testing of targeted molecular therapeutic strategies for GBM treatment. In this study, we profiled DNA copy number and mRNA expression in 21 independent GBM tumor lines maint...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-113

    authors: Hodgson JG,Yeh RF,Ray A,Wang NJ,Smirnov I,Yu M,Hariono S,Silber J,Feiler HS,Gray JW,Spellman PT,Vandenberg SR,Berger MS,James CD

    更新日期:2009-10-01 00:00:00

  • A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

    abstract:BACKGROUND:Several lines of evidence suggest a T cell-mediated immune response in paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS). In order to investigate whether suppression of T cell-mediated immune responses in Hu-PNS patients improved their neurological outcome, we performed a prospective ope...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou126

    authors: de Jongste AH,van Gelder T,Bromberg JE,de Graaf MT,Gratama JW,Schreurs MW,Hooijkaas H,Sillevis Smitt PA

    更新日期:2015-01-01 00:00:00

  • Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.

    abstract:BACKGROUND:While standards for the treatment of newly diagnosed glioblastomas exist, therapeutic regimens for tumor recurrence remain mostly individualized. The role of a surgical resection of recurrent glioblastomas remains largely unclear at present. This study aimed to assess the effect of repeated resection of recu...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1093/neuonc/nov145

    authors: Ringel F,Pape H,Sabel M,Krex D,Bock HC,Misch M,Weyerbrock A,Westermaier T,Senft C,Schucht P,Meyer B,Simon M,SN1 study group.

    更新日期:2016-01-01 00:00:00

  • High failure rate in spinal ependymomas with long-term follow-up.

    abstract::Data on spinal ependymomas are sparse, and prognostic factors remain controversial. The primary aim of this study is to review a historical cohort, with large patient numbers and long follow-up, and provide estimates of time to progression (TTP) and survival after progression. As a secondary aim, we assess the effects...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/S1152851704001231

    authors: Gomez DR,Missett BT,Wara WM,Lamborn KR,Prados MD,Chang S,Berger MS,Haas-Kogan DA

    更新日期:2005-07-01 00:00:00

  • Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.

    abstract::As immunotherapy assumes a central role in the management of many cancers, ongoing work is directed at understanding whether immune-based treatments will be successful in patients with glioblastoma (GBM). Despite several large studies conducted in the last several years, there remain no FDA-approved immunotherapies in...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa154

    authors: Dunn GP,Cloughesy TF,Maus MV,Prins RM,Reardon DA,Sonabend AM

    更新日期:2020-10-14 00:00:00

  • Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.

    abstract:INTRODUCTION:Surgery is first-line therapy for glioblastoma, and there is evidence that gross total resection is associated with improved survival. Gross total resection, however, is not always possible, and relationships among extent (percent) of resection (EOR), residual volume (RV), and survival are unknown. The goa...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not137

    authors: Chaichana KL,Jusue-Torres I,Navarro-Ramirez R,Raza SM,Pascual-Gallego M,Ibrahim A,Hernandez-Hermann M,Gomez L,Ye X,Weingart JD,Olivi A,Blakeley J,Gallia GL,Lim M,Brem H,Quinones-Hinojosa A

    更新日期:2014-01-01 00:00:00